Filmio Studios Unveils New Fan-Commitment Data Layer as Superfan Beta Reveals Early Greenlighting Signals 
Best SEO Software for Agencies: Tools Moving Services Are Using 
VyOS Networks Announces VyOS 1.4.4 LTS Release, Reinforcing the Universal Networking Platform for Hybrid Cloud and Edge Immutep’s Phase II TACTI-002 Study Reports Encouraging Data at SITC
Sydney, Australia, Nov. 10, 2020 (GLOBE NEWSWIRE) — ASX/Media Release Overall Response Rates (ORR)…
PDS Biotech Initiates VERSATILE-002 Phase 2 Combination Trial of PDS0101-KEYTRUDA® in Recurrent/Metastatic Head and Neck Cancer in Collaboration with Merck
VERSATILE-002 Trial for First Line Treatment of Recurrent/Metastatic Head and Neck Cancer with Combination PDS0101-KEYTRUDA®…
Tricida Announces Third Quarter 2020 Financial Results
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) — Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical…
Marrone Bio Innovations, Inc. Reports Third-Quarter 2020 Financial Results
Expansion in international and seed treatment markets led revenue growth and gross margin improvement DAVIS,…
Shockwave Medical Reports Third Quarter 2020 Financial Results
SANTA CLARA, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (Nasdaq: SWAV), a…
Altimmune Announces Third Quarter 2020 Financial Results and Provides a Business Update
GAITHERSBURG, Md., Nov. 09, 2020 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical…
Organogenesis Holdings Inc. Reports Third Quarter and Nine Months 2020 Financial Results
CANTON, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) — Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading…
Abeona Therapeutics Reports Third Quarter Financial Results
Conference call scheduled for Tuesday, November 10, 2020 at 8:30 a.m. ET NEW YORK and…
Homology Medicines Reports Third Quarter 2020 Financial Results and Recent Highlights
– Based on Positive Data, Advancing pheNIX Gene Therapy Clinical Trial for PKU to Dose…
Quotient Limited to Participate in Two Upcoming Conferences
JERSEY, Channel Islands, Nov. 09, 2020 (GLOBE NEWSWIRE) — Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics…
Editas Medicine to Present at Barclays Gene Editing & Gene Therapy Summit
CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a leading…
Novavax Reports Third Quarter 2020 Financial and Operational Results
Advanced clinical development of NVX‑CoV2373 with initiation of first Phase 3 trial to evaluate efficacy,…
Fulgent Genetics Reports Record Third Quarter 2020 Financial Results and Raises Full Year 2020 Revenue Guidance by $100 Million
Third Quarter 2020 Results: Record Revenue of $101.7 million, growing more than 880% year-over-year Record…
Progenity Provides Corporate Updates and Reports Third Quarter 2020 Financial Results
Reported 84 thousand tests in the third quarter, up 12% compared to the second quarter…
Novavax Appoints Gregory F. Covino as Chief Financial Officer and Announces Leadership Updates
Covino brings global biopharmaceutical finance experience to Novavax John Trizzino, Chief Business Officer, takes on…
Oncternal Therapeutics to Present at Stifel Virtual Healthcare Conference
SAN DIEGO, Nov. 09, 2020 (GLOBE NEWSWIRE) — Oncternal Therapeutics (Nasdaq: ONCT), today announced that…
Zogenix Provides Corporate Update and Reports Third Quarter 2020 Financial Results
FINTEPLA® (fenfluramine) oral solution launched in the U.S. in late July for Dravet syndrome with…
Affimed and Roivant Sciences Announce Licensing and Strategic Collaboration Agreement to Develop and Commercialize Novel Innate Cell Engagers (ICE®) for Multiple Cancer Targets
Affimed to grant license to AFM32 with options for additional ICE® molecules directed against…
First patient dosed with GLPG3667 in psoriasis patient Phase 1b trial
Mechelen, Belgium; 9 November 2020, 22.01 CET – Galapagos NV (Euronext & NASDAQ: GLPG) announces…
Kiniksa Announces American College of Rheumatology Convergence 2020 Late-Breaking Abstracts Presentation of Mavrilimumab Phase 2 Giant Cell Arteritis Data
Primary and secondary efficacy endpoints achieved statistical significance; mavrilimumab reduced risk of flare and increased…